Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,
Which biological targeted agent and for whom? Michel Ducreux Institut Gustave Roussy Villejuif.
